Citizens JMP Reiterates Market Perform Rating on Generation Bio (GBIO)

Citizens JMP analyst Silvan Tuerkcan reiterated a Market Perform rating on Generation Bio (NASDAQ: GBIO).

The analyst commented, “We view it as a positive that GBIO is leveraging its learnings from the Moderna (MRNA, NC) collaboration to modulate known, but hard-to-reach targets in I&I. While a timeline has been identified, we remain on the sidelines until there is greater clarity on the target and indications of interest.”

And, “The company ended 4Q24 with $185MM in cash. We maintain our Market Perform rating with the stock currently trading below its cash position, which we view as a fair discount consistent with other biotech companies with similar uncertainties.”

Also, “As previously announced, GBIO is now developing a T cell-selective LNP delivery system to develop siRNA therapeutics for T cell-driven autoimmune diseases. Novel developments include ctLNP delivery to T cells (see our coverage here and here), which has also sparked a collaboration with MRNA on separate applications.”

For an analyst ratings summary and ratings history on Generation Bio click here. For more ratings news on Generation Bio click here.

Shares of Generation Bio closed at $0.51 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Air T reports revenue jump but widens operating loss in Q1 fiscal 2027
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)